These data suggest that the ATXN3 locus in SCA3 patients in blood or buccal swab DNA might serve as a good biomarker for clinical trials testing suppressors of somatic expansion with peripheral exposure. This evidence concerns the gene ATXN3 and Spinocerebellar ataxia type 3.